Our Integrated Platform for Preclinical Biomarker Discovery
Access 1,000+ cancer cell lines, 600+ organoids, and 2,600+ PDX models for streamlined biomarker discovery across preclinical stages.
Select the right screening option tailored to your research phase, from high-throughput cell line screening to advanced PDX mouse clinical trials.
Opt for hypothesis-free discovery or targeted biomarker refinement, integrating multi-omics data and efficacy testing for reliable results.
Our bioinformatics team enhances every stage with expert support in model selection, study design, and data interpretation for actionable insights.
In vitro screening offers a high-throughput, cost-effective platform for early biomarker discovery and refinement, helping identify drug leads, targets, mechanisms of action (MoA), and genetic markers associated with drug response, and guide future in vivo model selection.
Our 2D cell lines and 3D tumor organoids provide rapid, data-driven insights, helping optimize early-stage research decisions.
Fig. Example workflow of in vitro compound screening
Explore Our In Vitro Screening Services:
- Custom Screens: Select from over 1,000 cancer cell lines or 600+ organoids with comprehensive model and standard-of-care (SOC) data. Our data scientists offer support in model selection and experimental design to ensure efficient, cost-effective outcomes.
- Cancer Cell Panel Screening Service: A quarterly high-throughput service with ~500 cancer cell lines, delivering significant cost savings. Cancer Cell Panel Screening is ideal for large-scale or targeted screening to assess cytotoxicity and chemotherapeutic potential in early drug development.
- Access unique subpanels categorized by cancer type, mutation, or in vivo model availability
- Screen a minimum of 50+ cell lines per run for maximum cost efficiency
- Includes positive controls and cell line revival costs
- OrganoidXplore™ Organoid Panel Screening: Process up to 60+ organoid models in as little as six weeks, enabling quick, data-driven decisions. This service includes a comprehensive repository of patient-derived organoids (PDO) and PDX-derived organoids (PDXO) with detailed mutational profiles, including KRAS, BRAF, and EGFR mutations.
- Model Diversity: Select from 60+ models with varied genetic backgrounds
- Multiple Panels: Choose from Full, KRAS, Lung, CRC, or Flexible Panels
- Cancer Type Coverage: Efficacy testing across seven cancer types, including lung, breast, ovarian, colorectal, pancreatic, cervical, and head & neck cancers
- PDX Transition: Seamlessly transition to in vivo studies with matched PDX models, supporting biomarker validation and patient response stratification
Did you know many oncology therapies fail in Phase II clinical trials due to a lack of efficacy? Crown Bioscience’s PDX Mouse Clinical Trials (MCTs) address this challenge by offering a robust, clinically relevant platform designed to improve the predictability of preclinical studies.
Figure. A representative PDX Mouse Clinical Trial Design
With the world’s largest collection of over 2,600 PDX models, our MCTs help bridge the gap between preclinical and clinical stages, enabling:
- Improved Clinical Translation: PDX models closely mimic patient tumors, providing reliable insights into clinical outcomes.
- Predictive Biomarker Discovery: Identify biomarkers for accurate patient stratification and increase clinical trial success rates.
- Exploration of New Indications: Access a diverse array of tumor types to expand research into drug efficacy.
- In-Depth Drug Efficacy and Resistance Analysis: Understand the mechanisms driving drug response to refine therapeutic approaches.
With 12+ years of experience and over 300 successful MCT projects, Crown Bioscience is your trusted partner, supporting the journey from preclinical studies to clinical validation with unmatched expertise and resources.
Related Services
Fast, reliable, accurate, and cost-effective laboratory services for data-driven decisions to meet your specific needs.
Well-validated in vitro screening program for rapid and cost-effective screening of ~500 cell lines.
Preclinical oncology drug development and validation using tumor organoids and the HUB tumor organoid biobank.
![pdx-mouse-clinical[1]](https://www.crownbio.com/hubfs/chub_backup/pdx-mouse-clinical%5B1%5D.png)
